Abstracts & Posters 2025
| O1 | Autologous neutralising antibodies and effective CD8 T-cells maintain long-term HIV-1 post-intervention control Katie Fisher et al. |
| O2 | High intestinal fatty acid binding protein (I-FABP) predicts slow CD4 recovery in immunological non-responders of HIV Hanne Hestdal Gullaksen et al. |
| O3 | Trends in late HIV diagnosis and its association with education and income: a nationwide cohort study from 2003 to 2023 in Sweden Sara Falk et al. |
| O4 | Predictors of Critical Illness During Different COVID-19 Pandemic Phases Compared to Seasonal Influenza Josefine Beck-Friis et al. |
| O5 | Virological and biochemical responses of combination treatment with bulevirtide and pegylated-interferon up to w72 in CHD: results from SEE-D trial Habiba Kamal et al. |
| O6 | Immunomodulatory imide drugs (IMiDs) reinvigorate anti-HBV immunity ex vivo. Rachel Pascoe et al. |
| P1 | HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant from CCR5Δ32/Δ32 Sibling Donor Malin Holm Meyer-Myklestadl et al. |
| P2 | High Risk of Renal Outcomes After Type 2 Diabetes Mellitus in People with HIV vs without HIV: Findings From the Cohort Study on Morbidity and HIV in Sweden Isabela Killander Möller et al. |
| P3 | Biomarkers of neuronal injury and neuroinflammation after switching to dolutegravir/lamivudine in people with HIV Linn Renborg et al. |
| P4 | CD4 Cell Count Trends After The Most Common Cancers in People With HIV: A Multicohort Collaboration Alisa Timiryasova et al. |
| P5 | Risk of Income Loss in People Living With and Without HIV – a Comparative Swedish Nationwide Study Between 2019 to 2021 Isabella Killander Möller et al. |
| P6 | Hypergammaglobulinemia in treated and untreated people with HIV Isabel Vigmo et al. |
| P7 | No association between plasma homocysteine and amyloid metabolism in people living with HIV Julia Kempa et al. |
| P8 | Effectiveness of mobile wireless technologies interventions for the prevention of vertical transmission: A systematic review and meta-analysis Winfred Mwangi et al. |
| P9 | Clinical characteristics and reasons for switching to long-acting cabotegravir + rilpivirine in routine care: Insights from the Nordic VALHALLA study Liisa Lehtoranta et al. |
| P10 | Nurse-Led Sexual Health Services for Priority Populations: 40 Years of Innovation at WAAC in Western Australia Garry Kuchel et al. |
| P11 | Evaluation of blood sampling with standardised filter paper technology for commercial molecular and serological analysis of hepatitis B-, C and HIV Anna Maria Delis et al. |
| P12 | Risk of Long COVID Symptoms and Conditions After SARS-CoV-2 Compared to Other Respiratory Viral Infections: A Systematic Review and Meta-Analysis Julia Fonseca de Morais Caporali et al. |
| P13 | The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: emulated target trial John Karlsson Valik et al. |
| P14 | Good flare or bad flare? ALT variability predicts outcome after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B Marte Holmberg et al. |
| P15 | Toward Hepatitis C Elimination in Denmark: We “C” a Major Prevalence Decline, but Remaining Gaps to Reach WHO 2030 Goals Exist Signe Freja Storgaard et al. |
| P16 | Long-term risk for hepatocellular carcinoma in 1,167 African-born patients with chronic hepatitis B living in Sweden Katarina Johansson Århem et al. |
| P17 | Limited value of repeated quantitative HBsAg for clinical management of chronic HBV infection – stability over time and impact on reactivation risk Catharina Alexandersson et al. |